Skip to main content
Defiance International

Published study records

Study records for GHK-Cu

Study records describe published research and its limitations. They do not establish efficacy, safety, or suitability for any use.

Study record counts

6,841 study records.

10 evidence-verified · 77 citation-verified · 6,753 identifier-confirmed · 1 citation-only

Listed by tier, then records with a public summary first, then publication year, newest first, undated last.

Verified records by research setting

  • In vitro: 27
  • In vivo/preclinical: 18
  • Review/meta-analysis: 34
  • Other: 0
Filter study recordsReset filters

Filtered results

Study type not established · Verification: PMID confirmed at PubMed

  • 2026

Synthesis, Characterization, and Anti-Plasmodium falciparum Activity of a New Copper(II) Complex Containing 2-(Tert-Butoxy)-6-(1H-imidazol-1-yl)pyridine.

ChemMedChem · 2026

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

PMID confirmed at PubMed. The PMID shown was confirmed at PubMed on 2026-09-14: PubMed held a record under this identifier. This check confirms the identifier only, not the study type, the findings, or any relevance to a chemical sequence. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type not established · Verification: PMID confirmed at PubMed

  • 2026

DNA/BSA binding, antidiabetic and antioxidant studies of copper(ii) complexes derived from ONO-tridentate Schiff bases and diimines as auxiliary ligands.

RSC advances · 2026

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

PMID confirmed at PubMed. The PMID shown was confirmed at PubMed on 2026-09-14: PubMed held a record under this identifier. This check confirms the identifier only, not the study type, the findings, or any relevance to a chemical sequence. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type not established · Verification: PMID confirmed at PubMed

  • 2026

Mimicking LPMO Active Sites with Synthetic copper(II) Complexes: Exploring the Minimal Requirements.

Inorganic chemistry · 2026

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

PMID confirmed at PubMed. The PMID shown was confirmed at PubMed on 2026-09-14: PubMed held a record under this identifier. This check confirms the identifier only, not the study type, the findings, or any relevance to a chemical sequence. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type not established · Verification: PMID confirmed at PubMed

  • 2026

Field-induced slow magnetic relaxation, molecular docking and antibacterial studies of quasi-isotropic copper(II) (S = 1⁄2) systems stabilised by tetradentate (ONNO) and tridentate (NNO)-donor ligands.

Dalton transactions (Cambridge, England : 2003) · 2026

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

PMID confirmed at PubMed. The PMID shown was confirmed at PubMed on 2026-09-14: PubMed held a record under this identifier. This check confirms the identifier only, not the study type, the findings, or any relevance to a chemical sequence. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type not established · Verification: PMID confirmed at PubMed

  • 2026

Antiproliferation and Anti-invasion Activity of Binuclear Copper(II) Complex in BRAFi-Resistant Melanoma Cells.

ACS pharmacology & translational science · 2026

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

PMID confirmed at PubMed. The PMID shown was confirmed at PubMed on 2026-10-21: PubMed held a record under this identifier. This check confirms the identifier only, not the study type, the findings, or any relevance to a chemical sequence. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type not established · Verification: PMID confirmed at PubMed

  • 2026

Integrated Multi-Endpoint Analysis of Soluble Copper(II) Chloride-Induced Oxidative Stress, Mitochondrial Dysfunction, and Genotoxicity in RAW264.7 Macrophages.

Biological trace element research · 2026

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

PMID confirmed at PubMed. The PMID shown was confirmed at PubMed on 2026-09-14: PubMed held a record under this identifier. This check confirms the identifier only, not the study type, the findings, or any relevance to a chemical sequence. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type not established · Verification: PMID confirmed at PubMed

  • 2026

Electronic effects of 4'-aryl substitution in terpyridine copper(II) complexes: structural insights, DNA-binding affinity, and cytotoxic evaluation.

Dalton transactions (Cambridge, England : 2003) · 2026

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

PMID confirmed at PubMed. The PMID shown was confirmed at PubMed on 2026-09-14: PubMed held a record under this identifier. This check confirms the identifier only, not the study type, the findings, or any relevance to a chemical sequence. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type not established · Verification: PMID confirmed at PubMed

  • 2026

Solvent influenced synthesis, crystal structures and urease inhibition of copper(II) complexes derived from 2-hydroxy-3-methoxybenzaldehyde thiosemicarbazone.

Acta chimica Slovenica · 2026

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

PMID confirmed at PubMed. The PMID shown was confirmed at PubMed on 2026-10-21: PubMed held a record under this identifier. This check confirms the identifier only, not the study type, the findings, or any relevance to a chemical sequence. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type not established · Verification: PMID confirmed at PubMed

  • 2026

Enantioselective copper(II) catalysed (4 + 1) cycloaddition of aza-o-quinone methides and bromomalonates. Facile access to enantioenriched indolines.

Organic & biomolecular chemistry · 2026

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

PMID confirmed at PubMed. The PMID shown was confirmed at PubMed on 2026-09-14: PubMed held a record under this identifier. This check confirms the identifier only, not the study type, the findings, or any relevance to a chemical sequence. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type not established · Verification: PMID confirmed at PubMed

  • 2026

Switching Copper(II)-Catalytic Process for the Selective Access to C3-Imidazolyl- and Pyridylquinoxalin-2(1H)-ones.

The Journal of organic chemistry · 2026

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

PMID confirmed at PubMed. The PMID shown was confirmed at PubMed on 2026-09-14: PubMed held a record under this identifier. This check confirms the identifier only, not the study type, the findings, or any relevance to a chemical sequence. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type not established · Verification: PMID confirmed at PubMed

  • 2026

Decomposition process of copper(ii) formate tetrahydrate through molecular dynamics simulations.

RSC advances · 2026

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

PMID confirmed at PubMed. The PMID shown was confirmed at PubMed on 2026-10-21: PubMed held a record under this identifier. This check confirms the identifier only, not the study type, the findings, or any relevance to a chemical sequence. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type not established · Verification: DOI confirmed at Crossref

  • 2026

Synthesis, Elemental Analysis, and Mössbauer Characterization of Copper(II), Iron(III), Zinc(II), Manganese(II), and Chromium(III) Complexes of Bisantrene and Anthracen-9-Imidazoline Hydrazone

Chemistry · 2026

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

DOI confirmed at Crossref. The DOI shown was confirmed at Crossref on 2026-10-25: Crossref held a registration for this identifier. This check confirms the identifier only, not the kind of work, the findings, or any relevance to a chemical sequence. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.